Newron Pharmaceut. Stock
Price
Target price
€21.35
€21.35
-0.230%
-
-0.230%
-
22:26 / Tradegate
WKN: A0LF18 / Name: Newron Pharmaceut. / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
The full analysis of the stock Newron Pharmaceut. is only available for our menbers.
Not a member yet? Sign up for free!
Not a member yet? Sign up for free!
Financial data and news for Newron Pharmaceut.
sharewise wants to provide you with the best news and tools for Newron Pharmaceut., so we directly link to the best financial data sources.
Financials
News
EQS-News: Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
EQS-News: Newron announces the US initiation of its ENIGMA-TRS 2 Phase III global clinical study with evenamide as an add-on therapy for patients with treatment-resistant schizophrenia (TRS)
EQS-News: Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
EQS-News: Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
EQS-News: Newron presents H1 2025 results and provides business update
EQS-News: Newron presents H1 2025 results and provides business update
EQS-News: Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)
EQS-News: Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)
EQS-News: Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
EQS-News: Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
EQS-News: Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
EQS-News: Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction